Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B
Background & Aims: In hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHBe-), interferon (IFN) achieves very low biochemical sustained response rates. No information exists on retreatment. Methods: Two hundred sixteen CHBe- patients treated for 5 or 12 months with 3 MU IFN-α2b thrice...
Gespeichert in:
| Veröffentlicht in: | Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2001-07, Vol.121 (1), p.101-109 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 109 |
|---|---|
| container_issue | 1 |
| container_start_page | 101 |
| container_title | Gastroenterology (New York, N.Y. 1943) |
| container_volume | 121 |
| creator | Manesis, Emanuel K. Hadziyannis, Stephanos J. |
| description | Background & Aims:
In hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHBe-), interferon (IFN) achieves very low biochemical sustained response rates. No information exists on retreatment.
Methods:
Two hundred sixteen CHBe- patients treated for 5 or 12 months with 3 MU IFN-α2b thrice weekly and retreated (51 patients, 60 courses) because of no response or relapse were retrospectively analyzed.
Results:
After 7.0 years of median follow-up, 39 naive patients (18.1%) were still in biochemical and virologic remission after a single IFN course. Longer treatment and a biochemical response within 4 months were significant predictors, inversely related to relapse by multivariate analysis (relative hazard [RH], 0.611; 95% confidence interval [CI], 0.448–0.834 and RH, 0.290; 95% Cl, 0.192–0.438, respectively). Retreatment resulted in 18.4% sustained response by intention-to-treat (18 of 98 patients). Patients with sustained response had persistently normal alanine aminotransferase levels, undetectable hepatitis B virus (HBV) DNA by molecular hybridization, and significant improvement of histologic grade, and 32% of them lost hepatitis B surface antigen. In sustained responders, serum HBV DNA was undetectable or very low at the end of treatment and at the end of follow-up (median 3934 and 903 copies/mL, respectively) by quantitative polymerase chain reaction.
Conclusions:
IFN induced long-term biochemical and virologic remission in approximately 18% of naive or retreated patients with CHBe-. Sustained responders exhibited significant histologic improvement and a high rate of HBsAg loss. |
| doi_str_mv | 10.1053/gast.2001.25524 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70991554</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0016508501185331</els_id><sourcerecordid>70991554</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-a90d18cca1abb54b38abe51c014d0ad969ace5be55f13228b2811661b1f2b04c3</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlbP3iQH8bZtJrup2WMtfhREQepRQjY7WyNttiap4M_yj_ibTG1RL56GeXnmZXgIOQbWBybywUyH2OeMQZ8LwYsd0gXBZZYCvku6aQwzwaTokIMQXhhjZS5hn3QAilwWpeySp4mL6Bv0raOfH3TqUccFuki1q-kDxp-9begNLnW00QZ6QZGOXLQzdNkdzlL6hnT8nEqs-Ysdkr1GzwMebWePPF5dTsc32e399WQ8us1MAXnMdMlqkMZo0FUliiqXukIBhkFRM12Xw1IbFCkSDeScy4pLgOEQKmh4xQqT98jZpnfp29cVhqgWNhicz7XDdhXUOStLEKJI4GADGt-G4LFRS28X2r8rYGptVK2NqrVR9W00XZxsq1fVAutffqswAadbQAej543Xztjwp1cIASxh5QbD5OHNolfBWHQGa-vRRFW39t8fvgCETpKq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70991554</pqid></control><display><type>article</type><title>Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Alma/SFX Local Collection</source><creator>Manesis, Emanuel K. ; Hadziyannis, Stephanos J.</creator><creatorcontrib>Manesis, Emanuel K. ; Hadziyannis, Stephanos J.</creatorcontrib><description>Background & Aims:
In hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHBe-), interferon (IFN) achieves very low biochemical sustained response rates. No information exists on retreatment.
Methods:
Two hundred sixteen CHBe- patients treated for 5 or 12 months with 3 MU IFN-α2b thrice weekly and retreated (51 patients, 60 courses) because of no response or relapse were retrospectively analyzed.
Results:
After 7.0 years of median follow-up, 39 naive patients (18.1%) were still in biochemical and virologic remission after a single IFN course. Longer treatment and a biochemical response within 4 months were significant predictors, inversely related to relapse by multivariate analysis (relative hazard [RH], 0.611; 95% confidence interval [CI], 0.448–0.834 and RH, 0.290; 95% Cl, 0.192–0.438, respectively). Retreatment resulted in 18.4% sustained response by intention-to-treat (18 of 98 patients). Patients with sustained response had persistently normal alanine aminotransferase levels, undetectable hepatitis B virus (HBV) DNA by molecular hybridization, and significant improvement of histologic grade, and 32% of them lost hepatitis B surface antigen. In sustained responders, serum HBV DNA was undetectable or very low at the end of treatment and at the end of follow-up (median 3934 and 903 copies/mL, respectively) by quantitative polymerase chain reaction.
Conclusions:
IFN induced long-term biochemical and virologic remission in approximately 18% of naive or retreated patients with CHBe-. Sustained responders exhibited significant histologic improvement and a high rate of HBsAg loss.</description><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1053/gast.2001.25524</identifier><identifier>PMID: 11438498</identifier><identifier>CODEN: GASTAB</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Female ; Hepatitis B e Antigens - blood ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - immunology ; Hepatitis B, Chronic - pathology ; Humans ; Immunomodulators ; Interferon alpha-2 ; Interferon-alpha - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Proportional Hazards Models ; Recombinant Proteins ; Retrospective Studies</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 2001-07, Vol.121 (1), p.101-109</ispartof><rights>2001 The American Gastroenterological Association</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-a90d18cca1abb54b38abe51c014d0ad969ace5be55f13228b2811661b1f2b04c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0016508501185331$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1055510$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11438498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Manesis, Emanuel K.</creatorcontrib><creatorcontrib>Hadziyannis, Stephanos J.</creatorcontrib><title>Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><description>Background & Aims:
In hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHBe-), interferon (IFN) achieves very low biochemical sustained response rates. No information exists on retreatment.
Methods:
Two hundred sixteen CHBe- patients treated for 5 or 12 months with 3 MU IFN-α2b thrice weekly and retreated (51 patients, 60 courses) because of no response or relapse were retrospectively analyzed.
Results:
After 7.0 years of median follow-up, 39 naive patients (18.1%) were still in biochemical and virologic remission after a single IFN course. Longer treatment and a biochemical response within 4 months were significant predictors, inversely related to relapse by multivariate analysis (relative hazard [RH], 0.611; 95% confidence interval [CI], 0.448–0.834 and RH, 0.290; 95% Cl, 0.192–0.438, respectively). Retreatment resulted in 18.4% sustained response by intention-to-treat (18 of 98 patients). Patients with sustained response had persistently normal alanine aminotransferase levels, undetectable hepatitis B virus (HBV) DNA by molecular hybridization, and significant improvement of histologic grade, and 32% of them lost hepatitis B surface antigen. In sustained responders, serum HBV DNA was undetectable or very low at the end of treatment and at the end of follow-up (median 3934 and 903 copies/mL, respectively) by quantitative polymerase chain reaction.
Conclusions:
IFN induced long-term biochemical and virologic remission in approximately 18% of naive or retreated patients with CHBe-. Sustained responders exhibited significant histologic improvement and a high rate of HBsAg loss.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Hepatitis B, Chronic - pathology</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Proportional Hazards Models</subject><subject>Recombinant Proteins</subject><subject>Retrospective Studies</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LAzEQhoMotlbP3iQH8bZtJrup2WMtfhREQepRQjY7WyNttiap4M_yj_ibTG1RL56GeXnmZXgIOQbWBybywUyH2OeMQZ8LwYsd0gXBZZYCvku6aQwzwaTokIMQXhhjZS5hn3QAilwWpeySp4mL6Bv0raOfH3TqUccFuki1q-kDxp-9begNLnW00QZ6QZGOXLQzdNkdzlL6hnT8nEqs-Ysdkr1GzwMebWePPF5dTsc32e399WQ8us1MAXnMdMlqkMZo0FUliiqXukIBhkFRM12Xw1IbFCkSDeScy4pLgOEQKmh4xQqT98jZpnfp29cVhqgWNhicz7XDdhXUOStLEKJI4GADGt-G4LFRS28X2r8rYGptVK2NqrVR9W00XZxsq1fVAutffqswAadbQAej543Xztjwp1cIASxh5QbD5OHNolfBWHQGa-vRRFW39t8fvgCETpKq</recordid><startdate>20010701</startdate><enddate>20010701</enddate><creator>Manesis, Emanuel K.</creator><creator>Hadziyannis, Stephanos J.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010701</creationdate><title>Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B</title><author>Manesis, Emanuel K. ; Hadziyannis, Stephanos J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-a90d18cca1abb54b38abe51c014d0ad969ace5be55f13228b2811661b1f2b04c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Hepatitis B, Chronic - pathology</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Proportional Hazards Models</topic><topic>Recombinant Proteins</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Manesis, Emanuel K.</creatorcontrib><creatorcontrib>Hadziyannis, Stephanos J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Manesis, Emanuel K.</au><au>Hadziyannis, Stephanos J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>2001-07-01</date><risdate>2001</risdate><volume>121</volume><issue>1</issue><spage>101</spage><epage>109</epage><pages>101-109</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><coden>GASTAB</coden><abstract>Background & Aims:
In hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHBe-), interferon (IFN) achieves very low biochemical sustained response rates. No information exists on retreatment.
Methods:
Two hundred sixteen CHBe- patients treated for 5 or 12 months with 3 MU IFN-α2b thrice weekly and retreated (51 patients, 60 courses) because of no response or relapse were retrospectively analyzed.
Results:
After 7.0 years of median follow-up, 39 naive patients (18.1%) were still in biochemical and virologic remission after a single IFN course. Longer treatment and a biochemical response within 4 months were significant predictors, inversely related to relapse by multivariate analysis (relative hazard [RH], 0.611; 95% confidence interval [CI], 0.448–0.834 and RH, 0.290; 95% Cl, 0.192–0.438, respectively). Retreatment resulted in 18.4% sustained response by intention-to-treat (18 of 98 patients). Patients with sustained response had persistently normal alanine aminotransferase levels, undetectable hepatitis B virus (HBV) DNA by molecular hybridization, and significant improvement of histologic grade, and 32% of them lost hepatitis B surface antigen. In sustained responders, serum HBV DNA was undetectable or very low at the end of treatment and at the end of follow-up (median 3934 and 903 copies/mL, respectively) by quantitative polymerase chain reaction.
Conclusions:
IFN induced long-term biochemical and virologic remission in approximately 18% of naive or retreated patients with CHBe-. Sustained responders exhibited significant histologic improvement and a high rate of HBsAg loss.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11438498</pmid><doi>10.1053/gast.2001.25524</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0016-5085 |
| ispartof | Gastroenterology (New York, N.Y. 1943), 2001-07, Vol.121 (1), p.101-109 |
| issn | 0016-5085 1528-0012 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70991554 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antiviral Agents - therapeutic use Biological and medical sciences Female Hepatitis B e Antigens - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Hepatitis B, Chronic - pathology Humans Immunomodulators Interferon alpha-2 Interferon-alpha - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Proportional Hazards Models Recombinant Proteins Retrospective Studies |
| title | Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T14%3A23%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interferon%20%CE%B1%20Treatment%20and%20Retreatment%20of%20Hepatitis%20B%20e%20Antigen-Negative%20Chronic%20Hepatitis%20B&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Manesis,%20Emanuel%20K.&rft.date=2001-07-01&rft.volume=121&rft.issue=1&rft.spage=101&rft.epage=109&rft.pages=101-109&rft.issn=0016-5085&rft.eissn=1528-0012&rft.coden=GASTAB&rft_id=info:doi/10.1053/gast.2001.25524&rft_dat=%3Cproquest_cross%3E70991554%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70991554&rft_id=info:pmid/11438498&rft_els_id=S0016508501185331&rfr_iscdi=true |